Aileron Therapeutics Future Growth
Future criteria checks 0/6
Aileron TherapeuticsDie Gewinne des Unternehmens werden voraussichtlich um 16.5% pro Jahr sinken, während die jährlichen Einnahmen um 100.1% pro Jahr steigen werden. Der Gewinn pro Aktie wird voraussichtlich grow um 38.3% pro Jahr steigen.
Key information
-16.5%
Earnings growth rate
38.3%
EPS growth rate
Biotechs earnings growth | 20.9% |
Revenue growth rate | 100.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 01 Dec 2023 |
Recent future growth updates
Recent updates
Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky
Aug 18Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?
Dec 30Aileron Therapeutics: An Assessment On A Lottery Ticket
Oct 21Aileron Therapeutics: Solving Chemotherapy's Toxicity
May 01Aileron Therapeutics +31% on insider buying more shares
Jan 08Aileron raises $40M via equity offering
Jan 06Aileron Therapeutics EPS in-line
Nov 13Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -38 | N/A | N/A | 1 |
12/31/2025 | N/A | -32 | N/A | N/A | 1 |
12/31/2024 | N/A | -27 | N/A | N/A | 1 |
12/31/2023 | N/A | -11 | N/A | N/A | 1 |
9/30/2023 | N/A | -13 | -14 | -14 | N/A |
6/30/2023 | N/A | -17 | -19 | -19 | N/A |
3/31/2023 | N/A | -24 | -22 | -22 | N/A |
12/31/2022 | N/A | -27 | -25 | -25 | N/A |
9/30/2022 | N/A | -30 | -27 | -27 | N/A |
6/30/2022 | N/A | -30 | -27 | -27 | N/A |
3/31/2022 | N/A | -28 | -25 | -25 | N/A |
12/31/2021 | N/A | -26 | -24 | -24 | N/A |
9/30/2021 | N/A | -24 | -22 | -22 | N/A |
6/30/2021 | N/A | -23 | -20 | -20 | N/A |
3/31/2021 | N/A | -21 | -21 | -21 | N/A |
12/31/2020 | N/A | -21 | -20 | -20 | N/A |
9/30/2020 | N/A | -23 | -22 | -22 | N/A |
6/30/2020 | N/A | -26 | -24 | -24 | N/A |
3/31/2020 | N/A | -29 | -25 | -25 | N/A |
12/31/2019 | N/A | -29 | -27 | -26 | N/A |
9/30/2019 | N/A | -29 | -29 | -27 | N/A |
6/30/2019 | N/A | -29 | -31 | -27 | N/A |
3/31/2019 | N/A | -31 | -33 | -28 | N/A |
12/31/2018 | N/A | -32 | -32 | -28 | N/A |
9/30/2018 | N/A | -31 | -30 | -27 | N/A |
6/30/2018 | N/A | -30 | -26 | -25 | N/A |
3/31/2018 | N/A | -26 | -22 | -22 | N/A |
12/31/2017 | N/A | -23 | -21 | -21 | N/A |
9/30/2017 | N/A | -20 | -19 | -19 | N/A |
6/30/2017 | N/A | -18 | N/A | -18 | N/A |
3/31/2017 | N/A | -19 | N/A | -17 | N/A |
12/31/2016 | N/A | -18 | N/A | -15 | N/A |
9/30/2016 | N/A | -17 | N/A | -14 | N/A |
6/30/2016 | N/A | -16 | N/A | -12 | N/A |
3/31/2016 | N/A | -14 | N/A | -12 | N/A |
12/31/2015 | N/A | -13 | N/A | -12 | N/A |
9/30/2015 | N/A | -13 | N/A | -13 | N/A |
6/30/2015 | N/A | -13 | N/A | -12 | N/A |
3/31/2015 | N/A | -15 | N/A | -15 | N/A |
12/31/2014 | N/A | -16 | N/A | -17 | N/A |
12/31/2013 | 22 | 0 | N/A | -14 | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: ALRN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: ALRN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: ALRN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: ALRN wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Hohe Wachstumseinnahmen: ALRN wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ALRN in 3 Jahren voraussichtlich hoch sein wird